88 related articles for article (PubMed ID: 26122182)
1. Gynaecological cancer: ADAMTS mutations predict sensitivity to chemotherapy in ovarian cancer.
Errico A
Nat Rev Clin Oncol; 2015 Sep; 12(9):504. PubMed ID: 26122182
[No Abstract] [Full Text] [Related]
2. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
3. Made-to-measure medicine: BRCA and gynaecological cancer.
Foulkes WD
Lancet Oncol; 2014 Jul; 15(8):783-5. PubMed ID: 24882435
[No Abstract] [Full Text] [Related]
4. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
5. Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain.
Delgado-Ortega L; Ginés Rubió J; Garcías de España MDC; Carcedo D; Cordero Puentes L; Moya de Alarcón C
Farm Hosp; 2018 May; 42(3):95-102. PubMed ID: 29730979
[TBL] [Abstract][Full Text] [Related]
6. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
Sokolenko AP; Savonevich EL; Ivantsov AO; Raskin GA; Kuligina ES; Gorodnova TV; Preobrazhenskaya EV; Kleshchov MA; Tiurin VI; Mukhina MS; Kotiv KB; Shulga AV; Kuznetsov SG; Berlev IV; Imyanitov EN
Cancer Lett; 2017 Jul; 397():127-132. PubMed ID: 28377179
[TBL] [Abstract][Full Text] [Related]
7. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
Moran-Jones K; Gloss BS; Murali R; Chang DK; Colvin EK; Jones MD; Yuen S; Howell VM; Brown LM; Wong CW; Spong SM; Scarlett CJ; Hacker NF; Ghosh S; Mok SC; Birrer MJ; Samimi G
Oncotarget; 2015 Dec; 6(42):44551-62. PubMed ID: 26575166
[TBL] [Abstract][Full Text] [Related]
8. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.
Lee YJ; Lee MY; Ruan A; Chen CK; Liu HP; Wang CJ; Chao WR; Han CP
Oncotarget; 2016 Dec; 7(50):82097-82103. PubMed ID: 27888800
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitors in BRCA mutation-associated ovarian cancer.
Clamp A; Jayson G
Lancet Oncol; 2015 Jan; 16(1):10-2. PubMed ID: 25481790
[No Abstract] [Full Text] [Related]
10. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
[TBL] [Abstract][Full Text] [Related]
11. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
[TBL] [Abstract][Full Text] [Related]
12. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
George A; Kristeleit R; Rafii S; Michie CO; Bowen R; Michalarea V; van Hagen T; Wong M; Rallis G; Molife LR; Lopez J; Banerji U; Banerjee SN; Gore ME; de Bono JS; Kaye SB; Yap TA
Eur J Cancer; 2017 May; 76():52-59. PubMed ID: 28273485
[TBL] [Abstract][Full Text] [Related]
13. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
14. A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis.
Yin X; Wang X; Shen B; Jing Y; Li Q; Cai MC; Gu Z; Yang Q; Zhang Z; Liu J; Li H; Di W; Zhuang G
Sci Rep; 2016 Aug; 6():31079. PubMed ID: 27498762
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
[TBL] [Abstract][Full Text] [Related]
16.
Na K; Kim EK; Jang W; Kim HS
Anticancer Res; 2017 Jun; 37(6):3249-3258. PubMed ID: 28551672
[TBL] [Abstract][Full Text] [Related]
17. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
Zanotti L; Romani C; Tassone L; Todeschini P; Tassi RA; Bandiera E; Damia G; Ricci F; Ardighieri L; Calza S; Marchini S; Beltrame L; Tognon G; D'Incalci M; Pecorelli S; Sartori E; Odicino F; Ravaggi A; Bignotti E
BMC Cancer; 2017 May; 17(1):366. PubMed ID: 28545541
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
[TBL] [Abstract][Full Text] [Related]
19. Ovarian function during chemotherapy with paclitaxel and carboplatin.
Ohara N
J Obstet Gynaecol; 2002 Mar; 22(2):226-7. PubMed ID: 12528710
[No Abstract] [Full Text] [Related]
20. Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.
Weiderpass E; Tyczynski JE
Mol Diagn Ther; 2015 Dec; 19(6):351-64. PubMed ID: 26476542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
